Clinical characteristics at diagnosis in75 FLT3-ITD-positive patients with AML
| Variable . | Midostaurin-treated (n = 54) . | Control group (n = 21) . | P . |
|---|---|---|---|
| Age, y | .94 | ||
| Median (range) | 52 (20-70) | 52 (23-71) | |
| Sex, n (%) | .12 | ||
| Male | 30 (56) | 7 (33) | |
| Female | 24 (44) | 14 (67) | |
| AML history, n (%) | .35 | ||
| De novo | 49 (91) | 21 (100) | |
| sAML | 3 (6) | 0 (0) | |
| tAML | 2 (3) | 0 (0) | |
| Cytogenetics, n (%) | .24 | ||
| Normal karyotype | 36 (67) | 18 (86) | |
| Other | 14 (26) | 3 (14) | |
| Not available | 4 (7) | 0 (0) | |
| Leukocytes, ×109/L* | .75 | ||
| Median (range) | 45 (2-304) | 35 (6-253) | |
| Blasts BM, %† | .75 | ||
| Median (range) | 80 (30-100) | 90 (31-95) | |
| Blasts PB, %‡ | .42 | ||
| Median (range) | 58 (0-98) | 68 (0-94) | |
| Induction cycles, n (%) | .05 | ||
| 1 | 40 (74) | 10 (48) | |
| 2 | 14 (26) | 11 (52) | |
| Consolidation, n (%) | .30 | ||
| HDAC | 32 (48) | 19 (90) | |
| Allogeneic HSCT in CR1 | 9 (17) | 2 (10) | |
| Not available§ | 19 (35) | 0 (0) | |
| Midostaurin maintenance | ND | ||
| Patients, n (%) | 23 (43) | 0 (0) | |
| Cycles, median (range) | 8 (1-12) | ||
| Time from diagnosis to refractory disease/relapse | .29 | ||
| No. of days, median (range) | 252 (21-1451) | 253 (121-1339) |
| Variable . | Midostaurin-treated (n = 54) . | Control group (n = 21) . | P . |
|---|---|---|---|
| Age, y | .94 | ||
| Median (range) | 52 (20-70) | 52 (23-71) | |
| Sex, n (%) | .12 | ||
| Male | 30 (56) | 7 (33) | |
| Female | 24 (44) | 14 (67) | |
| AML history, n (%) | .35 | ||
| De novo | 49 (91) | 21 (100) | |
| sAML | 3 (6) | 0 (0) | |
| tAML | 2 (3) | 0 (0) | |
| Cytogenetics, n (%) | .24 | ||
| Normal karyotype | 36 (67) | 18 (86) | |
| Other | 14 (26) | 3 (14) | |
| Not available | 4 (7) | 0 (0) | |
| Leukocytes, ×109/L* | .75 | ||
| Median (range) | 45 (2-304) | 35 (6-253) | |
| Blasts BM, %† | .75 | ||
| Median (range) | 80 (30-100) | 90 (31-95) | |
| Blasts PB, %‡ | .42 | ||
| Median (range) | 58 (0-98) | 68 (0-94) | |
| Induction cycles, n (%) | .05 | ||
| 1 | 40 (74) | 10 (48) | |
| 2 | 14 (26) | 11 (52) | |
| Consolidation, n (%) | .30 | ||
| HDAC | 32 (48) | 19 (90) | |
| Allogeneic HSCT in CR1 | 9 (17) | 2 (10) | |
| Not available§ | 19 (35) | 0 (0) | |
| Midostaurin maintenance | ND | ||
| Patients, n (%) | 23 (43) | 0 (0) | |
| Cycles, median (range) | 8 (1-12) | ||
| Time from diagnosis to refractory disease/relapse | .29 | ||
| No. of days, median (range) | 252 (21-1451) | 253 (121-1339) |